250 related articles for article (PubMed ID: 9225945)
1. Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft.
Stribbling SM; Martin J; Pedley RB; Boden JA; Sharma SK; Springer CJ
Cancer Chemother Pharmacol; 1997; 40(4):277-84. PubMed ID: 9225945
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
Pedley RB; Sharma SK; Boxer GM; Boden R; Stribbling SM; Davies L; Springer CJ; Begent RH
Cancer Res; 1999 Aug; 59(16):3998-4003. PubMed ID: 10463598
[TBL] [Abstract][Full Text] [Related]
3. Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein.
Bhatia J; Sharma SK; Chester KA; Pedley RB; Boden RW; Read DA; Boxer GM; Michael NP; Begent RH
Int J Cancer; 2000 Feb; 85(4):571-7. PubMed ID: 10699932
[TBL] [Abstract][Full Text] [Related]
4. Plasma clearance of an antibody--enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo.
Rogers GT; Burke PJ; Sharma SK; Koodie R; Boden JA
Br J Cancer; 1995 Dec; 72(6):1357-63. PubMed ID: 8519645
[TBL] [Abstract][Full Text] [Related]
5. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma.
Napier MP; Sharma SK; Springer CJ; Bagshawe KD; Green AJ; Martin J; Stribbling SM; Cushen N; O'Malley D; Begent RH
Clin Cancer Res; 2000 Mar; 6(3):765-72. PubMed ID: 10741695
[TBL] [Abstract][Full Text] [Related]
6. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial.
Martin J; Stribbling SM; Poon GK; Begent RH; Napier M; Sharma SK; Springer CJ
Cancer Chemother Pharmacol; 1997; 40(3):189-201. PubMed ID: 9219501
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.
Blakey DC; Davies DH; Dowell RI; East SJ; Burke PJ; Sharma SK; Springer CJ; Mauger AB; Melton RG
Br J Cancer; 1995 Nov; 72(5):1083-8. PubMed ID: 7577451
[TBL] [Abstract][Full Text] [Related]
8. Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material.
Webley SD; Francis RJ; Pedley RB; Sharma SK; Begent RH; Hartley JA; Hochhauser D
Br J Cancer; 2001 Jun; 84(12):1671-6. PubMed ID: 11401322
[TBL] [Abstract][Full Text] [Related]
9. ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts.
Blakey DC; Burke PJ; Davies DH; Dowell RI; East SJ; Eckersley KP; Fitton JE; McDaid J; Melton RG; Niculescu-Duvaz IA; Pinder PE; Sharma SK; Wright AF; Springer CJ
Cancer Res; 1996 Jul; 56(14):3287-92. PubMed ID: 8764123
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug.
Blakey DC; Valcaccia BE; East S; Wright AF; Boyle FT; Springer CJ; Burke PJ; Melton RG; Bagshawe KD
Cell Biophys; 1993; 22(1-3):1-8. PubMed ID: 7889535
[TBL] [Abstract][Full Text] [Related]
11. Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy.
Sharma SK; Pedley RB; Bhatia J; Boxer GM; El-Emir E; Qureshi U; Tolner B; Lowe H; Michael NP; Minton N; Begent RH; Chester KA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):814-25. PubMed ID: 15701872
[TBL] [Abstract][Full Text] [Related]
12. Antibody-directed enzyme prodrug therapy (ADEPT). A three-phase study in ovarian tumor xenografts.
Sharma SK; Boden JA; Springer CJ; Burke PJ; Bagshawe KD
Cell Biophys; 1994; 24-25():219-28. PubMed ID: 7736526
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.
Mayer A; Francis RJ; Sharma SK; Tolner B; Springer CJ; Martin J; Boxer GM; Bell J; Green AJ; Hartley JA; Cruickshank C; Wren J; Chester KA; Begent RH
Clin Cancer Res; 2006 Nov; 12(21):6509-16. PubMed ID: 17085666
[TBL] [Abstract][Full Text] [Related]
14. Antibody directed enzyme prodrug therapy (ADEPT): a three phase system.
Sharma SK; Bagshawe KD; Springer CJ; Burke PJ; Rogers GT; Boden JA; Antoniw P; Melton RG; Sherwood RF
Dis Markers; 1991; 9(3-4):225-31. PubMed ID: 1813212
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours.
Francis RJ; Sharma SK; Springer C; Green AJ; Hope-Stone LD; Sena L; Martin J; Adamson KL; Robbins A; Gumbrell L; O'Malley D; Tsiompanou E; Shahbakhti H; Webley S; Hochhauser D; Hilson AJ; Blakey D; Begent RH
Br J Cancer; 2002 Sep; 87(6):600-7. PubMed ID: 12237768
[TBL] [Abstract][Full Text] [Related]
16. Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy.
Sharma SK; Bagshawe KD; Burke PJ; Boden JA; Rogers GT; Springer CJ; Melton RG; Sherwood RF
Cancer; 1994 Feb; 73(3 Suppl):1114-20. PubMed ID: 8306255
[TBL] [Abstract][Full Text] [Related]
17. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination.
Marais R; Spooner RA; Light Y; Martin J; Springer CJ
Cancer Res; 1996 Oct; 56(20):4735-42. PubMed ID: 8840992
[TBL] [Abstract][Full Text] [Related]
18. Altered biodistribution of an antibody--enzyme conjugate modified with polyethylene glycol.
Eno-Amooquaye EA; Searle F; Boden JA; Sharma SK; Burke PJ
Br J Cancer; 1996 Jun; 73(11):1323-7. PubMed ID: 8645574
[TBL] [Abstract][Full Text] [Related]
19. Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185.
Eccles SA; Court WJ; Box GA; Dean CJ; Melton RG; Springer CJ
Cancer Res; 1994 Oct; 54(19):5171-7. PubMed ID: 7923136
[TBL] [Abstract][Full Text] [Related]
20. Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model.
Sharma SK; Bagshawe KD; Burke PJ; Boden RW; Rogers GT
Br J Cancer; 1990 May; 61(5):659-62. PubMed ID: 2337503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
